• American Heart Association http://www.heart.org/HEARTORG/
• American Society of Clinical Onocology http://www.asco.org/

..

• The Endocrine Society http://www.endo-society.org/
• The Goddess Fund http://www.thegoddessfund.org/
• The Hormone Foundation http://www.hormone.org
• International Menopause Society http://www.imsociety.org/
• National Osteoporosis Foundation http://www.nof.org/
• North American Menopause Society http://menopause.org
• U.S. Food and Drug Administration http://www.fda.gov/ForConsumers/byAudience/ForWomen/default.htm
• Kronos Early Estrogen Prevention Study (KEEPS) http://www.keepstudy.org
• National Cancer Institute http://www.cancer.gov/cancertopics/types/breast
• National Center for Complementary and Alternative Medicine  http://nccam.nih.gov
• Study of Women's Health Across the Nation  http://www.swanstudy.org
• Women's Health Initiative of the National Heart, Lung, & Blood Institute at National Institute of Health http://www.nhlbi.nih.gov/whi/

Additional Publications:

• Bedell S, et al. The pros and cons of plant estrogen for menopause. J Steroid biochem mol Biol, 2012.
• Davies E, et al. Is Timing Everything: A meeting report of the Society for Womens' Health Research Roundtable on Menopausal Hormone Therapy. J of Women's Health. 2013.
• Gold E. et al. Phytoestrogen and fiber intakes in relation to incident vasomotor symptoms. Menopause. 2012.
• Greendale GA, et al. Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women's Health Across the Nation (SWAN). J Bone Min Res. 2012.
• Joffe H, Crawford S, Economou N, et al. A gonadotropin-releasing hormone agonist model demonstrates that nocturnal hot flashes interrupt objective sleep. Sleep. 2013;36:1977-1985. Abstract
• Lobo RA et al.  Prevention of diseases after menopause.  Climacteric.  June 27, 2014.  doi:10.3109/13697137.2014.933411  Abstract
• Manson JE et al. New findings from the the Kronos early estrogen prevention study randomized trials. NAMS. 2012.
• Manson JE et al.  Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women’s Health Initiative Randomized Trials. JAMA. October 2013.
• Manson JE et al.  Editorial:  Why the Product Labeling for Low-Dose Vaginal Estrogen Should be Changed.  Menopause. 2014;21(9)
• Menopausal Hormone Therapy to Prevent Chronic Conditions: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine. 2012.
• Minkin MJ, Guess MK. Diagnosis and Treatment of the Non–Sex-related Symptoms of Vulvovaginal Atrophy. The Female Patient. Vol 37. 2012.
• Obstet Gynecol. Practice Bulletin. 2014;123:202-216. Abstract
• Parrish SJ et al.  Impact of vulvovaginal health on postmenopausal women:   A review of surveys on symptoms of volvovaginal atrophy.  Inter. J. of Women's Health. 2013:5.
• Position Statement: The 2012 Hormone Therapy Position Statement of the North American Menopause Society. Menopause. 2012.
• Roussouw JE, Prentice RL, Manson JE, et al. Postmenopause hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007.
• Santen R, Stuenkel C, Burger H, Manson JE.  Competency in Menopause Management:  Whither Goest the Internist. Journal of Women's Health.  2014.
• Schierbeck ,LL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomized trial. BMJ. 2012.
• Shapiro S, et al. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies. J Fam Plann Reprod Health Care. 2011.
• Stuenkel C et al. Special Feature: A decade after the Women's Health Initiative—the expert agree. Menopause: The Journal of the North American Menopause Society. 2013.

Other Sources: 

Women's Health Research Institute sponsored-lectures presented by Hrayr Attarian, MD., Stacy Tessler Lindau, MD, Pauline Maki, PhD, Bethanee Schlosser, PhD, MD, Catherine Stika, MD, Lauren Streicher, MD.